Psychosomatic Medicine Tips for Better Browsing
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kupfer, D. J.
Right arrow Articles by Rubinstein, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kupfer, D. J.
Right arrow Articles by Rubinstein, D.

Psychosomatic Medicine, Vol 41, Issue 7 535-544, Copyright © 1979 by American Psychosomatic Society


ORIGINAL ARTICLES

Changes in weight during treatment for depression

DJ Kupfer, PA Coble and D Rubinstein

Changes in appetite and weight were examined in a group of 47 carefully diagnosed primary depressives who were treated in a random design with either placebo (N = 17) or amitryptyline (N = 30) over a 35-day protocol. While the amitriptyline treated group as a whole showed a greater gain in weight than did the placebo group (4.5 vs. 0.5 lb, p less than 0.05), no differential effects could be demonstrated between drug responders and nonresponders. Likewise, while a consistent relationship between the self-report of decreased appetite and final weight change was noted in the placebo group, no simple relationship between final weight change and self-reported changes in appetite were apparent in the drug-treated patients. There was, however, a relationship between the report of decreased appetite and clinical severity of depression in the drug nonresponder subgroup despite significant weight gain during the protocol. Thus, weight change during this study period did not appear to show a simple relationship to corresponding clinical change. The clinical lore that has supported the notion that increased appetite and weight gain in patients being treated with tricyclic antidepressants are "good" signs cannot be confirmed by our findings.


This article has been cited by other articles:


Home page
Psychiatr. Serv.Home page
Y. Vanina, A. Podolskaya, K. Sedky, H. Shahab, A. Siddiqui, F. Munshi, and S. Lippmann
Body Weight Changes Associated With Psychopharmacology
Psychiatr Serv, July 1, 2002; 53(7): 842 - 847.
[Abstract] [Full Text] [PDF]


Home page
Br. J. PsychiatryHome page
C. BARBUI and M. HOTOPF
Amitriptyline v. the rest: still the leading antidepressant after 40 years of randomised controlled trials
The British Journal of Psychiatry, February 1, 2001; 178(2): 129 - 144.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1979 by the American Psychosomatic Society